The Chemours Company Reports Second Quarter 2025 Results
Business Wire2 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company ('Chemours' or 'the Company') (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ('TSS'), Titanium Technologies ('TT'), and Advanced Performance Materials ('APM'), today announced its financial results for the second quarter 2025.
Key Second Quarter 2025 Results & Highlights 1
Net Sales of $1.6 billion, a 4% increase compared to the corresponding prior-year quarter, with TSS achieving year-over-year growth of 65% in Opteon™ Refrigerants
Net Loss attributable to Chemours of $381 million, or $2.54 per diluted share, compared with Net Income attributable to Chemours of $60 million, or $0.39 per diluted share, in the corresponding prior-year quarter
Adjusted Net Income 2 of $87 million, or $0.58 per diluted share, compared to $58 million, or $0.38 per diluted share, in the corresponding prior-year quarter
Adjusted EBITDA 2,3 of $253 million compared to $207 million in the corresponding prior-year quarter
Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS
Declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025
'Our results surpassed our expectations for the quarter, with improved performance across each of our three businesses driven by strong demand for Opteon™, volume growth in TT, and favorable pricing in APM. We also made significant progress against Pathway to Thrive through our Strengthening the Long Term pillar, reaching a settlement to comprehensively resolve all statewide environmental claims, including those related to PFAS in New Jersey,' said Denise Dignam, Chemours President and CEO. 'We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward.'
Total Chemours
Second quarter 2025 Net Sales were $1.6 billion, a 4% increase compared to the prior-year quarter. The increase in Net Sales was primarily driven by a 3% increase in volume and a 1% increase in price. The increase in volumes was primarily driven by increased Opteon™ Refrigerant blends volumes in TSS. Increased pricing was driven by stronger aftermarket demand for Opteon™ Refrigerant blends in TSS and strong pricing in APM's Advanced Materials portfolio, partially offset by TT pricing.
Second quarter 2025 Net Loss attributable to Chemours was $381 million, or $2.54 per diluted share, compared to Net Income attributable to Chemours of $60 million, or $0.39 per diluted share in the prior-year quarter, primarily driven by litigation-related charges pertaining to the announced settlement with the State of New Jersey 4 and related tax impacts. Adjusted EBITDA for the second quarter of 2025 was $253 million, compared to $207 million in the prior-year quarter. The increase in Adjusted EBITDA was primarily driven by the referenced volume and pricing dynamics and lower Corporate Expenses. This was partially offset by higher input and operational costs in TT, lower fixed cost absorption in APM, and minor input cost increases in TSS.
____________________
1 As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025.
2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)'.
3 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.
4 $257 million of litigation-related charges pertaining to the announced settlement with the state of New Jersey were recorded within Selling, general, and administrative expense for the second quarter of 2025.
Expand
Thermal & Specialized Solutions
Q2 2025
Q2 2024
Y-o-Y % ∆
Q1 2025
Q-o-Q % ∆
Net Sales (millions)
$597
$519
15%
$466
28%
Opteon™ Refrigerants
$375
$227
65%
$279
34%
Freon™ Refrigerants
$123
$173
(29)%
$97
27%
Foam, Propellants & Other (FP&O)
$99
$119
(17)%
$90
10%
Adjusted EBITDA (millions)
$207
$160
29%
$141
47%
Adjusted EBITDA Margin
35%
31%
4 ppts
30%
5 ppts
Expand
TSS segment second quarter 2025 Net Sales were $597 million, a 15% increase compared to the second quarter 2024. Net Sales growth was primarily driven by a volume increase of 11% and a price increase of 4%, while currency impact remained flat. Volume growth was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning ('AC') transition under the U.S. AIM Act, partially offset by lower volumes for Freon™ Refrigerant products under this regulatory transition. The increase in pricing was primarily attributed to stronger Opteon™ Refrigerant aftermarket demand.
TSS segment second quarter 2025 Adjusted EBITDA increased 29% to $207 million compared to the prior-year quarter, while Adjusted EBITDA Margin also increased 4 percentage points to 35%. This increase was driven primarily by the previously mentioned increases in volume and price as a result of increased demand for Opteon™ Refrigerant blends products in connection with the stationary AC regulatory transition, partially offset by minor input cost increases.
On a sequential basis, Net Sales increased by 28%, driven by a volume increase of 19% and a price increase of 8%, with favorable currency movements adding a slight 1% tailwind. Overall volume and price increases were primarily related to typical seasonal trends across refrigerant products and the increased demand for Opteon™ Refrigerant blends in connection with the stationary AC transition under the U.S. AIM Act.
Titanium Technologies
TT segment second quarter 2025 Net Sales were $657 million, a 3% decrease compared to the second quarter 2024. This decrease was primarily driven by a 4% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes remained generally flat overall, with stronger demand in North America and Europe offsetting lower volumes in other non-western markets.
TT segment second quarter 2025 Adjusted EBITDA decreased 43% to $47 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 7%. The decline was driven in part by the previously mentioned decrease in price, partially offset by the favorable currency movements. TT operations were also disrupted by a now resolved external rail issue in the second quarter of 2025, which impacted feedstock mix, while also experiencing unrelated operational disruptions. In order to supply its customers, the Company elected to consume higher-cost ore feedstock, which resulted in incremental costs of $15 million in the second quarter. The net costs associated with other operational disruptions were $8 million for the quarter.
On a sequential basis, TT segment second quarter 2025 Net Sales increased 10%, driven by a 9% increase in volume across all regions, partially offset by a 1% decrease in price, with favorable currency movements adding a 2% tailwind.
Advanced Performance Materials
APM segment second quarter 2025 Net Sales of $346 million were in line with the prior-year quarter. A 6% increase in price was offset by a 6% decrease in volume, while currency impact remained flat. The increase in pricing was primarily driven by stronger pricing in high-value applications as well as pricing opportunities associated with the SPS Capstone™ product line's exit 5. The decrease in volume was primarily driven by weakness in cyclical end markets impacting Advanced Materials and products serving the hydrogen markets under Performance Solutions.
APM segment second quarter 2025 Adjusted EBITDA increased 11% to $50 million compared to the prior-year quarter, while Adjusted EBITDA Margin increased 1 percentage point to 14%. The increase was primarily due to the previously mentioned increase in price, partially offset by lower fixed cost absorption due to lower overall volumes.
On a sequential basis, APM segment second quarter 2025 Net Sales increased by 18%, driven by a 14% increase in volume and a 2% increase in price, with favorable currency movements adding a 2% tailwind.
Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the second quarter 2025 of $15 million and $4 million, respectively.
Corporate Expenses 6
Corporate Expenses were a $53 million offset to Adjusted EBITDA in the second quarter 2025, a decrease of $24 million compared to the prior-year quarter. This was primarily due to lower costs associated with the Audit Committee's internal review and the 2024 material weakness remediation.
Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS
On August 4 th, 2025, Chemours, DuPont and Corteva, Inc. announced a settlement with the State of New Jersey to comprehensively resolve all environmental claims, including PFAS. This settlement resolves such matters across four current and former operating sites, providing for payments over 25 years with a net present value of approximately $250 million to Chemours. In connection with this settlement, earlier this week, Chemours also established an agreement with DuPont and Corteva to acquire Chemours' rights to certain PFAS-related insurance proceeds, providing $150 million to be used to fund the New Jersey settlement payments. The combination of this $150 million and the expected release of the approximately $50 million in restricted cash from the 2021 MOU escrow account is anticipated to fully fund Chemours' payment obligations under the New Jersey settlement through 2030. The present value of payments remaining after 2030 by Chemours for the New Jersey settlement is approximately $80 million prior to the consideration of additional PFAS-related insurance recoveries. Amounts related to the settlement are included in Selling, General and Administrative costs in the second quarter of 2025 and are excluded from Adjusted EBITDA.
Liquidity and Capital Allocation
As of June 30, 2025, consolidated gross debt was $4.2 billion. Debt, net of $502 million in unrestricted cash and cash equivalents, was $3.7 billion, resulting in a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $502 million in unrestricted cash and cash equivalents and $954 million of revolving credit facility capacity, net of outstanding letters of credit.
Cash provided by operating activities for the second quarter of 2025 was $93 million, compared to operating cash usage of $620 million in the prior-year quarter. The improvement in operating cash flows in the second quarter of 2025 compared with the prior-year quarter was primarily due to the release of the $606 million of restricted cash and restricted cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.
Capital expenditures for the second quarter of 2025 amounted to $43 million, a decrease in spend compared to $73 million in the prior-year quarter, driven by lower capital expenditures in APM and TSS.
Free Cash Flows for the second quarter of 2025 reflected a positive $50 million. During the quarter, the Company paid $13 million in dividends to shareholders.
Effective August 5, 2025, the Company's Board of Directors declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025. The dividend will be paid on September 12, 2025, to stockholders of record as of the close of business on August 15, 2025.
Third Quarter 2025 Outlook
In the third quarter, the Company anticipates consolidated Net Sales to decrease 4-6% sequentially, with consolidated Adjusted EBITDA expected to range between $175 million and $195 million. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to decrease approximately 5%. The Company also anticipates capital expenditures to be approximately $50 million, with Free Cash Flow Conversion to be between 60-80%.
TSS expects a sequential Net Sales decrease in the mid single-digit percentage range, driven by overall traditional refrigerant seasonality concentrated in Freon™ Refrigerants. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially, primarily driven by the referenced seasonality as well as overall product mix.
TT expects a sequential Net Sales decrease in the low single-digit percentage range, driven by seasonality and regional sales mix, with volumes expected to remain stable. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially due to lower sales paired with certain operational disruptions. Costs associated with these operational issues are anticipated to approximate $15 million in the third quarter.
APM expects a sequential Net Sales decrease in the mid-teens percentage range due to production constraints associated with an outage at our Washington Works U.S. site. Adjusted EBITDA for APM is expected to approximate $15 million in the third quarter, considering lower sales as well as additional costs from the referenced site outage, which are anticipated to approximate $20 million.
Full Year 2025 Outlook
The Company expects to deliver Net Sales of $5.9 billion to $6.0 billion and Adjusted EBITDA of $775 million to $825 million in 2025, with referenced Q3 operational disruptions in TT and outage impacts in APM totaling $35M, collectively, to be resolved in the fourth quarter. Anticipated capital expenditures are expected to be approximately $250 million, with Free Cash Flow Conversion to be between 60-80% in the second half of 2025 through a seasonal net working capital unwind.
Conference Call
As previously announced, Chemours will hold a conference call and webcast on August 6, 2025, at 8:00 AM Eastern Daylight Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the US or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
The Chemours Company
Consolidated Balance Sheets (Unaudited) 1
(Dollars in millions, except per share amounts)
June 30, 2025
Assets
Current assets:
Cash and cash equivalents
$
502
$
713
Accounts and notes receivable, net
959
770
Inventories
1,558
1,463
Prepaid expenses and other
58
71
Assets held for sale
23
—
Total current assets
3,100
3,017
Property, plant, and equipment
9,781
9,572
Less: Accumulated depreciation
(6,660
)
(6,389
)
Property, plant, and equipment, net
3,121
3,183
Operating lease right-of-use assets
281
258
Goodwill
46
46
Other intangible assets, net
2
3
Investments in affiliates
177
152
Restricted cash and restricted cash equivalents
51
50
Other assets
710
804
Total assets
$
7,488
$
7,513
Liabilities
Current liabilities:
Accounts payable
$
1,023
$
1,156
Compensation and other employee-related cost
79
99
Short-term and current maturities of long-term debt
38
54
Current environmental remediation
102
115
Other accrued liabilities
608
393
Total current liabilities
1,850
1,817
Long-term debt, net
4,102
4,054
Operating lease liabilities
206
194
Long-term environmental remediation
503
456
Deferred income taxes
23
35
Other liabilities
565
369
Total liabilities
7,249
6,925
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,545,179 shares issued and 149,698,300 shares outstanding at June 30, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024)
2
2
Treasury stock, at cost (48,846,879 shares at June 30, 2025 and 48,871,602 at December 31, 2024)
(1,803
)
(1,804
)
Additional paid-in capital
1,066
1,055
Retained earnings
1,265
1,701
Accumulated other comprehensive loss
(293
)
(367
)
Total Chemours stockholders' equity
237
587
Non-controlling interests
2
1
Total equity
239
588
Total liabilities and equity
$
7,488
$
7,513
Expand
The Chemours Company
Consolidated Statements of Cash Flows (Unaudited) 1
(Dollars in millions)
Six Months Ended June 30,
2025
2024
Cash flows from operating activities
Net (loss) income
$
(384
)
$
113
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization
180
145
Gain on sales of assets and businesses
(1
)
(3
)
Equity in earnings of affiliates, net
(16
)
(20
)
Amortization of debt issuance costs and issue discounts
6
6
Deferred tax provision (benefit)
84
(15
)
Asset-related charges
11
—
Stock-based compensation expense
12
7
Net periodic pension cost
—
2
Defined benefit plan contributions
(8
)
(7
)
Other operating charges and credits, net
14
(18
)
Decrease (increase) in operating assets:
Accounts and notes receivable, net
(174
)
(287
)
Inventories and other current operating assets
(42
)
(9
)
Other non-current operating assets
64
52
(Decrease) increase in operating liabilities:
Accounts payable
(87
)
(175
)
Other current operating liabilities
83
(690
)
Other non-current operating liabilities
239
(11
)
Cash used for operating activities
(19
)
(910
)
Cash flows from investing activities
Purchases of property, plant, and equipment
(127
)
(175
)
Proceeds from sales of assets and businesses
1
3
Foreign exchange contract settlements, net
(2
)
(1
)
Other investing activities
—
2
Cash used for investing activities
(128
)
(171
)
Cash flows from financing activities
Proceeds from issuance of debt, net
95
—
Debt repayments
(111
)
(5
)
Payments of debt issuance cost
(4
)
—
Payments on finance leases
(7
)
(6
)
Proceeds from supplier financing program
47
47
Payments to supplier financing program
(53
)
(61
)
Proceeds from exercised stock options, net
—
8
Payments related to tax withholdings on vested stock awards
(1
)
(3
)
Payments of dividends to the Company's common shareholders
(50
)
(74
)
Cash used for financing activities
(84
)
(94
)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents
21
(13
)
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents
(210
)
(1,188
)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,
763
1,807
Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,
$
553
$
619
Supplemental cash flows information
Non-cash investing and financing activities:
Purchases of property, plant, and equipment included in accounts payable
$
26
$
44
Expand
The Chemours Company
Segment Financial and Operating Data (Unaudited)
(Dollars in millions)
Segment Net Sales 1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2025
2024
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
597
$
519
$
78
$
466
$
131
Titanium Technologies
657
677
(20
)
597
60
Advanced Performance Materials
346
345
1
294
52
Other Non-Reportable Segment
15
13
2
11
4
Total Net Sales
$
1,615
$
1,554
$
61
$
1,368
$
247
Expand
Segment Adjusted EBITDA 1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2025
2024
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
207
$
160
$
47
$
141
$
66
Titanium Technologies
$
47
$
83
$
(36
)
$
50
$
(3
)
Advanced Performance Materials
$
50
$
45
$
5
$
32
$
18
Other Non-Reportable Segment
$
4
$
3
$
1
$
1
$
3
Expand
Quarterly Change in Net Sales from the three months ended June 30, 2024
June 30, 2025
Percentage Change vs.
Percentage Change Due To
Net Sales
June 30, 2024
Price
Volume
Currency
Portfolio
Total Company
$
1,615
4
%
1
%
3
%
—
%
—
%
Thermal & Specialized Solutions
$
597
15
%
4
%
11
%
—
%
—
%
Titanium Technologies
657
(3
)%
(4
)%
—
%
1
%
—
%
Advanced Performance Materials
346
—
%
6
%
(6
)%
—
%
—
%
Other Non-Reportable Segment
15
15
%
1
%
14
%
—
%
—
%
Expand
Quarterly Change in Net Sales from the three months ended March 31, 2025
June 30, 2025
Percentage Change vs.
Percentage Change Due To
Net Sales
March 31, 2025
Price
Volume
Currency
Portfolio
Total Company
$
1,615
18
%
3
%
14
%
1
%
—
%
Thermal & Specialized Solutions
$
597
28
%
8
%
19
%
1
%
—
%
Titanium Technologies
657
10
%
(1
)%
9
%
2
%
—
%
Advanced Performance Materials
346
18
%
2
%
14
%
2
%
—
%
Other Non-Reportable Segment
15
36
%
(1
)%
37
%
—
%
—
%
Expand
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation 1
Adjusted earnings before interest, taxes, depreciation, and amortization ('Adjusted EBITDA') is defined as (loss) income before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net (loss) income attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Three Months Ended
Six Months Ended
Twelve Months Ended
June 30,
March 31,
June 30,
June 30,
2025
2024
2025
2025
2024
2025
2024
(Loss) income before income taxes
$
(261
)
$
69
$
—
$
(262
)
$
138
$
(292
)
$
79
Net (loss) income attributable to Chemours
$
(381
)
$
60
$
(4
)
$
(385
)
$
113
$
(427
)
$
106
Non-operating pension and other post-retirement benefit income
(2
)
(2
)
(2
)
(4
)
(2
)
(5
)
(3
)
Exchange losses, net
4
7
3
7
6
10
32
Restructuring, asset-related, and other charges (1)
18
3
32
50
7
100
145
Goodwill impairment charge (2)
—
—
—
—
—
56
—
Loss on extinguishment of debt
—
—
—
—
—
1
1
Gain on sales of assets and businesses, net (3)
—
—
(1
)
(1
)
(3
)
(1
)
(113
)
Transaction costs (4)
2
—
—
2
—
4
16
Qualified spend recovery (5)
(13
)
(8
)
(9
)
(22
)
(15
)
(33
)
(37
)
Litigation-related charges (6)
299
(1
)
—
299
(6
)
302
112
Environmental charges (7)
60
—
—
60
—
75
8
Adjustments made to income taxes (8)
171
(4
)
—
172
(3
)
178
(17
)
(Benefit from) provision for income taxes relating to reconciling items (9)
(71
)
3
—
(71
)
8
(83
)
(38
)
Adjusted Net Income
87
58
19
107
105
177
212
Net income attributable to non-controlling interests
1
—
—
1
—
1
—
Interest expense, net
67
66
66
133
128
268
247
Depreciation and amortization (10)
79
74
77
157
145
304
297
All remaining provision for income taxes (9)
19
9
4
21
20
39
28
Adjusted EBITDA
$
253
$
207
$
166
$
419
$
398
$
789
$
784
Total debt principal
$
4,177
$
4,028
Less: Cash and cash equivalents
(502
)
(604
)
Total debt principal, net
$
3,675
$
3,424
Net Leverage Ratio (calculated using GAAP earnings) (11)
(12.6)x
43.3x
Net Leverage Ratio (calculated using Non-GAAP earnings) (11)
4.7x
4.4x
Expand
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued) 1
(1)
For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily includes charges related to our decision to exit our SPS Capstone TM business and the 2024 Restructuring Program. For the twelve months ended June 30, 2024, restructuring, asset-related and other charges primarily includes charges related to the Titanium Technologies Transformation Plan, shutdown of a production line at the Company's El Dorado site and charges related to the 2023 Restructuring Program. See "Note 4 – Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(2)
Represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2024.
(3)
For the twelve months ended June 30, 2024, gain on sales of assets and businesses, net includes pre-tax gain on sale of $106 million related to the Glycolic Acid Transaction.
(4)
For the twelve months ended June 30, 2024, transaction costs includes $7 million of costs associated with the Senior Secured Credit Facilities entered into during 2023 and $9 million of third-party costs related to the Titanium Technologies Transformation Plan.
(5)
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
(6)
Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2025, litigation-related charges includes $257 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $16 million of third-party legal fees directly related to the New Jersey settlement agreement, $14 million related to the Company's portion of Chemours and EID's settlement agreement to resolve the Hoosick Falls class action law suit, $12 million related to reserves for asbestos and production liability matters arising from an EID subsidiary, Sporting Goods Properties, Inc., and a $29 million accrual associated with the Ohio MDL, partially offset by $26 million of benefits from insurance recoveries. For the twelve months ended June 30, 2024, litigation-related charges includes a $7 million benefit related to insurance recoveries, $55 million of charges related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of Ohio's agreement entered into in November 2023, $13 million related to the Company's portion of the supplemental payment to the State of Delaware, $48 million for other PFAS litigation matters, and $3 million of other litigation matters. See "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(7)
Environmental charges pertains to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2025, environmental charges primarily includes changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(8)
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.
(9)
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
(10)
Accelerated depreciation charges of $12 million and $23 million incurred as part of our decision to exit our SPS Capstone TM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.
(11)
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by (loss) income before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Expand
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
Adjusted earnings per share ('Adjusted EPS') is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
(1)
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025 as Adjusted Net Income was in a net income position.
(2)
Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.
Expand
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
2025 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)
Low
High
Net loss attributable to Chemours
$
(336
)
$
(300
)
Restructuring, transaction, and other costs, net (2)
492
492
Adjusted Net Income
156
192
Interest expense, net
272
272
Depreciation and amortization
313
313
All remaining provision for income taxes
34
48
Adjusted EBITDA
$
775
$
825
Expand
(1)
The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.
(2)
Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.
Expand
Key Second Quarter 2025 Results & Highlights 1
Net Sales of $1.6 billion, a 4% increase compared to the corresponding prior-year quarter, with TSS achieving year-over-year growth of 65% in Opteon™ Refrigerants
Net Loss attributable to Chemours of $381 million, or $2.54 per diluted share, compared with Net Income attributable to Chemours of $60 million, or $0.39 per diluted share, in the corresponding prior-year quarter
Adjusted Net Income 2 of $87 million, or $0.58 per diluted share, compared to $58 million, or $0.38 per diluted share, in the corresponding prior-year quarter
Adjusted EBITDA 2,3 of $253 million compared to $207 million in the corresponding prior-year quarter
Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS
Declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025
'Our results surpassed our expectations for the quarter, with improved performance across each of our three businesses driven by strong demand for Opteon™, volume growth in TT, and favorable pricing in APM. We also made significant progress against Pathway to Thrive through our Strengthening the Long Term pillar, reaching a settlement to comprehensively resolve all statewide environmental claims, including those related to PFAS in New Jersey,' said Denise Dignam, Chemours President and CEO. 'We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward.'
Total Chemours
Second quarter 2025 Net Sales were $1.6 billion, a 4% increase compared to the prior-year quarter. The increase in Net Sales was primarily driven by a 3% increase in volume and a 1% increase in price. The increase in volumes was primarily driven by increased Opteon™ Refrigerant blends volumes in TSS. Increased pricing was driven by stronger aftermarket demand for Opteon™ Refrigerant blends in TSS and strong pricing in APM's Advanced Materials portfolio, partially offset by TT pricing.
Second quarter 2025 Net Loss attributable to Chemours was $381 million, or $2.54 per diluted share, compared to Net Income attributable to Chemours of $60 million, or $0.39 per diluted share in the prior-year quarter, primarily driven by litigation-related charges pertaining to the announced settlement with the State of New Jersey 4 and related tax impacts. Adjusted EBITDA for the second quarter of 2025 was $253 million, compared to $207 million in the prior-year quarter. The increase in Adjusted EBITDA was primarily driven by the referenced volume and pricing dynamics and lower Corporate Expenses. This was partially offset by higher input and operational costs in TT, lower fixed cost absorption in APM, and minor input cost increases in TSS.
____________________
1 As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025.
2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)'.
3 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.
4 $257 million of litigation-related charges pertaining to the announced settlement with the state of New Jersey were recorded within Selling, general, and administrative expense for the second quarter of 2025.
Expand
Thermal & Specialized Solutions
Q2 2025
Q2 2024
Y-o-Y % ∆
Q1 2025
Q-o-Q % ∆
Net Sales (millions)
$597
$519
15%
$466
28%
Opteon™ Refrigerants
$375
$227
65%
$279
34%
Freon™ Refrigerants
$123
$173
(29)%
$97
27%
Foam, Propellants & Other (FP&O)
$99
$119
(17)%
$90
10%
Adjusted EBITDA (millions)
$207
$160
29%
$141
47%
Adjusted EBITDA Margin
35%
31%
4 ppts
30%
5 ppts
Expand
TSS segment second quarter 2025 Net Sales were $597 million, a 15% increase compared to the second quarter 2024. Net Sales growth was primarily driven by a volume increase of 11% and a price increase of 4%, while currency impact remained flat. Volume growth was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning ('AC') transition under the U.S. AIM Act, partially offset by lower volumes for Freon™ Refrigerant products under this regulatory transition. The increase in pricing was primarily attributed to stronger Opteon™ Refrigerant aftermarket demand.
TSS segment second quarter 2025 Adjusted EBITDA increased 29% to $207 million compared to the prior-year quarter, while Adjusted EBITDA Margin also increased 4 percentage points to 35%. This increase was driven primarily by the previously mentioned increases in volume and price as a result of increased demand for Opteon™ Refrigerant blends products in connection with the stationary AC regulatory transition, partially offset by minor input cost increases.
On a sequential basis, Net Sales increased by 28%, driven by a volume increase of 19% and a price increase of 8%, with favorable currency movements adding a slight 1% tailwind. Overall volume and price increases were primarily related to typical seasonal trends across refrigerant products and the increased demand for Opteon™ Refrigerant blends in connection with the stationary AC transition under the U.S. AIM Act.
Titanium Technologies
TT segment second quarter 2025 Net Sales were $657 million, a 3% decrease compared to the second quarter 2024. This decrease was primarily driven by a 4% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes remained generally flat overall, with stronger demand in North America and Europe offsetting lower volumes in other non-western markets.
TT segment second quarter 2025 Adjusted EBITDA decreased 43% to $47 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 7%. The decline was driven in part by the previously mentioned decrease in price, partially offset by the favorable currency movements. TT operations were also disrupted by a now resolved external rail issue in the second quarter of 2025, which impacted feedstock mix, while also experiencing unrelated operational disruptions. In order to supply its customers, the Company elected to consume higher-cost ore feedstock, which resulted in incremental costs of $15 million in the second quarter. The net costs associated with other operational disruptions were $8 million for the quarter.
On a sequential basis, TT segment second quarter 2025 Net Sales increased 10%, driven by a 9% increase in volume across all regions, partially offset by a 1% decrease in price, with favorable currency movements adding a 2% tailwind.
Advanced Performance Materials
APM segment second quarter 2025 Net Sales of $346 million were in line with the prior-year quarter. A 6% increase in price was offset by a 6% decrease in volume, while currency impact remained flat. The increase in pricing was primarily driven by stronger pricing in high-value applications as well as pricing opportunities associated with the SPS Capstone™ product line's exit 5. The decrease in volume was primarily driven by weakness in cyclical end markets impacting Advanced Materials and products serving the hydrogen markets under Performance Solutions.
APM segment second quarter 2025 Adjusted EBITDA increased 11% to $50 million compared to the prior-year quarter, while Adjusted EBITDA Margin increased 1 percentage point to 14%. The increase was primarily due to the previously mentioned increase in price, partially offset by lower fixed cost absorption due to lower overall volumes.
On a sequential basis, APM segment second quarter 2025 Net Sales increased by 18%, driven by a 14% increase in volume and a 2% increase in price, with favorable currency movements adding a 2% tailwind.
Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the second quarter 2025 of $15 million and $4 million, respectively.
Corporate Expenses 6
Corporate Expenses were a $53 million offset to Adjusted EBITDA in the second quarter 2025, a decrease of $24 million compared to the prior-year quarter. This was primarily due to lower costs associated with the Audit Committee's internal review and the 2024 material weakness remediation.
Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS
On August 4 th, 2025, Chemours, DuPont and Corteva, Inc. announced a settlement with the State of New Jersey to comprehensively resolve all environmental claims, including PFAS. This settlement resolves such matters across four current and former operating sites, providing for payments over 25 years with a net present value of approximately $250 million to Chemours. In connection with this settlement, earlier this week, Chemours also established an agreement with DuPont and Corteva to acquire Chemours' rights to certain PFAS-related insurance proceeds, providing $150 million to be used to fund the New Jersey settlement payments. The combination of this $150 million and the expected release of the approximately $50 million in restricted cash from the 2021 MOU escrow account is anticipated to fully fund Chemours' payment obligations under the New Jersey settlement through 2030. The present value of payments remaining after 2030 by Chemours for the New Jersey settlement is approximately $80 million prior to the consideration of additional PFAS-related insurance recoveries. Amounts related to the settlement are included in Selling, General and Administrative costs in the second quarter of 2025 and are excluded from Adjusted EBITDA.
Liquidity and Capital Allocation
As of June 30, 2025, consolidated gross debt was $4.2 billion. Debt, net of $502 million in unrestricted cash and cash equivalents, was $3.7 billion, resulting in a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $502 million in unrestricted cash and cash equivalents and $954 million of revolving credit facility capacity, net of outstanding letters of credit.
Cash provided by operating activities for the second quarter of 2025 was $93 million, compared to operating cash usage of $620 million in the prior-year quarter. The improvement in operating cash flows in the second quarter of 2025 compared with the prior-year quarter was primarily due to the release of the $606 million of restricted cash and restricted cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.
Capital expenditures for the second quarter of 2025 amounted to $43 million, a decrease in spend compared to $73 million in the prior-year quarter, driven by lower capital expenditures in APM and TSS.
Free Cash Flows for the second quarter of 2025 reflected a positive $50 million. During the quarter, the Company paid $13 million in dividends to shareholders.
Effective August 5, 2025, the Company's Board of Directors declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025. The dividend will be paid on September 12, 2025, to stockholders of record as of the close of business on August 15, 2025.
Third Quarter 2025 Outlook
In the third quarter, the Company anticipates consolidated Net Sales to decrease 4-6% sequentially, with consolidated Adjusted EBITDA expected to range between $175 million and $195 million. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to decrease approximately 5%. The Company also anticipates capital expenditures to be approximately $50 million, with Free Cash Flow Conversion to be between 60-80%.
TSS expects a sequential Net Sales decrease in the mid single-digit percentage range, driven by overall traditional refrigerant seasonality concentrated in Freon™ Refrigerants. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially, primarily driven by the referenced seasonality as well as overall product mix.
TT expects a sequential Net Sales decrease in the low single-digit percentage range, driven by seasonality and regional sales mix, with volumes expected to remain stable. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially due to lower sales paired with certain operational disruptions. Costs associated with these operational issues are anticipated to approximate $15 million in the third quarter.
APM expects a sequential Net Sales decrease in the mid-teens percentage range due to production constraints associated with an outage at our Washington Works U.S. site. Adjusted EBITDA for APM is expected to approximate $15 million in the third quarter, considering lower sales as well as additional costs from the referenced site outage, which are anticipated to approximate $20 million.
Full Year 2025 Outlook
The Company expects to deliver Net Sales of $5.9 billion to $6.0 billion and Adjusted EBITDA of $775 million to $825 million in 2025, with referenced Q3 operational disruptions in TT and outage impacts in APM totaling $35M, collectively, to be resolved in the fourth quarter. Anticipated capital expenditures are expected to be approximately $250 million, with Free Cash Flow Conversion to be between 60-80% in the second half of 2025 through a seasonal net working capital unwind.
Conference Call
As previously announced, Chemours will hold a conference call and webcast on August 6, 2025, at 8:00 AM Eastern Daylight Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the US or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
The Chemours Company
Consolidated Balance Sheets (Unaudited) 1
(Dollars in millions, except per share amounts)
June 30, 2025
Assets
Current assets:
Cash and cash equivalents
$
502
$
713
Accounts and notes receivable, net
959
770
Inventories
1,558
1,463
Prepaid expenses and other
58
71
Assets held for sale
23
—
Total current assets
3,100
3,017
Property, plant, and equipment
9,781
9,572
Less: Accumulated depreciation
(6,660
)
(6,389
)
Property, plant, and equipment, net
3,121
3,183
Operating lease right-of-use assets
281
258
Goodwill
46
46
Other intangible assets, net
2
3
Investments in affiliates
177
152
Restricted cash and restricted cash equivalents
51
50
Other assets
710
804
Total assets
$
7,488
$
7,513
Liabilities
Current liabilities:
Accounts payable
$
1,023
$
1,156
Compensation and other employee-related cost
79
99
Short-term and current maturities of long-term debt
38
54
Current environmental remediation
102
115
Other accrued liabilities
608
393
Total current liabilities
1,850
1,817
Long-term debt, net
4,102
4,054
Operating lease liabilities
206
194
Long-term environmental remediation
503
456
Deferred income taxes
23
35
Other liabilities
565
369
Total liabilities
7,249
6,925
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,545,179 shares issued and 149,698,300 shares outstanding at June 30, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024)
2
2
Treasury stock, at cost (48,846,879 shares at June 30, 2025 and 48,871,602 at December 31, 2024)
(1,803
)
(1,804
)
Additional paid-in capital
1,066
1,055
Retained earnings
1,265
1,701
Accumulated other comprehensive loss
(293
)
(367
)
Total Chemours stockholders' equity
237
587
Non-controlling interests
2
1
Total equity
239
588
Total liabilities and equity
$
7,488
$
7,513
Expand
The Chemours Company
Consolidated Statements of Cash Flows (Unaudited) 1
(Dollars in millions)
Six Months Ended June 30,
2025
2024
Cash flows from operating activities
Net (loss) income
$
(384
)
$
113
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization
180
145
Gain on sales of assets and businesses
(1
)
(3
)
Equity in earnings of affiliates, net
(16
)
(20
)
Amortization of debt issuance costs and issue discounts
6
6
Deferred tax provision (benefit)
84
(15
)
Asset-related charges
11
—
Stock-based compensation expense
12
7
Net periodic pension cost
—
2
Defined benefit plan contributions
(8
)
(7
)
Other operating charges and credits, net
14
(18
)
Decrease (increase) in operating assets:
Accounts and notes receivable, net
(174
)
(287
)
Inventories and other current operating assets
(42
)
(9
)
Other non-current operating assets
64
52
(Decrease) increase in operating liabilities:
Accounts payable
(87
)
(175
)
Other current operating liabilities
83
(690
)
Other non-current operating liabilities
239
(11
)
Cash used for operating activities
(19
)
(910
)
Cash flows from investing activities
Purchases of property, plant, and equipment
(127
)
(175
)
Proceeds from sales of assets and businesses
1
3
Foreign exchange contract settlements, net
(2
)
(1
)
Other investing activities
—
2
Cash used for investing activities
(128
)
(171
)
Cash flows from financing activities
Proceeds from issuance of debt, net
95
—
Debt repayments
(111
)
(5
)
Payments of debt issuance cost
(4
)
—
Payments on finance leases
(7
)
(6
)
Proceeds from supplier financing program
47
47
Payments to supplier financing program
(53
)
(61
)
Proceeds from exercised stock options, net
—
8
Payments related to tax withholdings on vested stock awards
(1
)
(3
)
Payments of dividends to the Company's common shareholders
(50
)
(74
)
Cash used for financing activities
(84
)
(94
)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents
21
(13
)
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents
(210
)
(1,188
)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,
763
1,807
Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,
$
553
$
619
Supplemental cash flows information
Non-cash investing and financing activities:
Purchases of property, plant, and equipment included in accounts payable
$
26
$
44
Expand
The Chemours Company
Segment Financial and Operating Data (Unaudited)
(Dollars in millions)
Segment Net Sales 1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2025
2024
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
597
$
519
$
78
$
466
$
131
Titanium Technologies
657
677
(20
)
597
60
Advanced Performance Materials
346
345
1
294
52
Other Non-Reportable Segment
15
13
2
11
4
Total Net Sales
$
1,615
$
1,554
$
61
$
1,368
$
247
Expand
Segment Adjusted EBITDA 1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2025
2024
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
207
$
160
$
47
$
141
$
66
Titanium Technologies
$
47
$
83
$
(36
)
$
50
$
(3
)
Advanced Performance Materials
$
50
$
45
$
5
$
32
$
18
Other Non-Reportable Segment
$
4
$
3
$
1
$
1
$
3
Expand
Quarterly Change in Net Sales from the three months ended June 30, 2024
June 30, 2025
Percentage Change vs.
Percentage Change Due To
Net Sales
June 30, 2024
Price
Volume
Currency
Portfolio
Total Company
$
1,615
4
%
1
%
3
%
—
%
—
%
Thermal & Specialized Solutions
$
597
15
%
4
%
11
%
—
%
—
%
Titanium Technologies
657
(3
)%
(4
)%
—
%
1
%
—
%
Advanced Performance Materials
346
—
%
6
%
(6
)%
—
%
—
%
Other Non-Reportable Segment
15
15
%
1
%
14
%
—
%
—
%
Expand
Quarterly Change in Net Sales from the three months ended March 31, 2025
June 30, 2025
Percentage Change vs.
Percentage Change Due To
Net Sales
March 31, 2025
Price
Volume
Currency
Portfolio
Total Company
$
1,615
18
%
3
%
14
%
1
%
—
%
Thermal & Specialized Solutions
$
597
28
%
8
%
19
%
1
%
—
%
Titanium Technologies
657
10
%
(1
)%
9
%
2
%
—
%
Advanced Performance Materials
346
18
%
2
%
14
%
2
%
—
%
Other Non-Reportable Segment
15
36
%
(1
)%
37
%
—
%
—
%
Expand
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation 1
Adjusted earnings before interest, taxes, depreciation, and amortization ('Adjusted EBITDA') is defined as (loss) income before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net (loss) income attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Three Months Ended
Six Months Ended
Twelve Months Ended
June 30,
March 31,
June 30,
June 30,
2025
2024
2025
2025
2024
2025
2024
(Loss) income before income taxes
$
(261
)
$
69
$
—
$
(262
)
$
138
$
(292
)
$
79
Net (loss) income attributable to Chemours
$
(381
)
$
60
$
(4
)
$
(385
)
$
113
$
(427
)
$
106
Non-operating pension and other post-retirement benefit income
(2
)
(2
)
(2
)
(4
)
(2
)
(5
)
(3
)
Exchange losses, net
4
7
3
7
6
10
32
Restructuring, asset-related, and other charges (1)
18
3
32
50
7
100
145
Goodwill impairment charge (2)
—
—
—
—
—
56
—
Loss on extinguishment of debt
—
—
—
—
—
1
1
Gain on sales of assets and businesses, net (3)
—
—
(1
)
(1
)
(3
)
(1
)
(113
)
Transaction costs (4)
2
—
—
2
—
4
16
Qualified spend recovery (5)
(13
)
(8
)
(9
)
(22
)
(15
)
(33
)
(37
)
Litigation-related charges (6)
299
(1
)
—
299
(6
)
302
112
Environmental charges (7)
60
—
—
60
—
75
8
Adjustments made to income taxes (8)
171
(4
)
—
172
(3
)
178
(17
)
(Benefit from) provision for income taxes relating to reconciling items (9)
(71
)
3
—
(71
)
8
(83
)
(38
)
Adjusted Net Income
87
58
19
107
105
177
212
Net income attributable to non-controlling interests
1
—
—
1
—
1
—
Interest expense, net
67
66
66
133
128
268
247
Depreciation and amortization (10)
79
74
77
157
145
304
297
All remaining provision for income taxes (9)
19
9
4
21
20
39
28
Adjusted EBITDA
$
253
$
207
$
166
$
419
$
398
$
789
$
784
Total debt principal
$
4,177
$
4,028
Less: Cash and cash equivalents
(502
)
(604
)
Total debt principal, net
$
3,675
$
3,424
Net Leverage Ratio (calculated using GAAP earnings) (11)
(12.6)x
43.3x
Net Leverage Ratio (calculated using Non-GAAP earnings) (11)
4.7x
4.4x
Expand
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued) 1
(1)
For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily includes charges related to our decision to exit our SPS Capstone TM business and the 2024 Restructuring Program. For the twelve months ended June 30, 2024, restructuring, asset-related and other charges primarily includes charges related to the Titanium Technologies Transformation Plan, shutdown of a production line at the Company's El Dorado site and charges related to the 2023 Restructuring Program. See "Note 4 – Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(2)
Represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2024.
(3)
For the twelve months ended June 30, 2024, gain on sales of assets and businesses, net includes pre-tax gain on sale of $106 million related to the Glycolic Acid Transaction.
(4)
For the twelve months ended June 30, 2024, transaction costs includes $7 million of costs associated with the Senior Secured Credit Facilities entered into during 2023 and $9 million of third-party costs related to the Titanium Technologies Transformation Plan.
(5)
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
(6)
Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2025, litigation-related charges includes $257 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $16 million of third-party legal fees directly related to the New Jersey settlement agreement, $14 million related to the Company's portion of Chemours and EID's settlement agreement to resolve the Hoosick Falls class action law suit, $12 million related to reserves for asbestos and production liability matters arising from an EID subsidiary, Sporting Goods Properties, Inc., and a $29 million accrual associated with the Ohio MDL, partially offset by $26 million of benefits from insurance recoveries. For the twelve months ended June 30, 2024, litigation-related charges includes a $7 million benefit related to insurance recoveries, $55 million of charges related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of Ohio's agreement entered into in November 2023, $13 million related to the Company's portion of the supplemental payment to the State of Delaware, $48 million for other PFAS litigation matters, and $3 million of other litigation matters. See "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(7)
Environmental charges pertains to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2025, environmental charges primarily includes changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 16 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.
(8)
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.
(9)
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
(10)
Accelerated depreciation charges of $12 million and $23 million incurred as part of our decision to exit our SPS Capstone TM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.
(11)
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by (loss) income before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Expand
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
Adjusted earnings per share ('Adjusted EPS') is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
(1)
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025 as Adjusted Net Income was in a net income position.
(2)
Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.
Expand
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
2025 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)
Low
High
Net loss attributable to Chemours
$
(336
)
$
(300
)
Restructuring, transaction, and other costs, net (2)
492
492
Adjusted Net Income
156
192
Interest expense, net
272
272
Depreciation and amortization
313
313
All remaining provision for income taxes
34
48
Adjusted EBITDA
$
775
$
825
Expand
(1)
The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.
(2)
Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Snap Inc. (SNAP) Nosedives 17% on Wider Net Loss
We recently published . Snap Inc. (NYSE:SNAP) is one of the worst-performing stocks on Wednesday. Shares of Snap fell by 17.15 percent on Wednesday to close at $7.78 apiece, as investor sentiment was dampened by a higher net loss in the second quarter of the year. In its updated report, Snap Inc. (NYSE:SNAP) said net loss widened by 6 percent to $262 million from $248.6 million in the same period last year. Revenues grew by 9 percent to $1.345 billion from $1.236 billion year-on-year. Despite the dismal quarter, the company narrowed its net loss by 27 percent in the first half of the year to $402 million from $553.7 million in the same period last year. Revenues increased by 11 percent to $2.7 billion from $2.4 billion. Following the results, Snap Inc. (NYSE:SNAP) earned a lower price target of $10 from RBC Capital, as compared with the $12 previously. Still, the new figure marks a 28-percent upside from its latest closing price. RBC Capital described the second quarter as a 'tough Q2' for Snap Inc. (NYSE:SNAP), with planned ad platform development and surface expansion efforts not going according to plan. Additionally, RBC Capital said that the underperformance would 'continue to reinforce the bear case that SNAP cannot break out of being a smaller ad platform lacking the ability to durably grow its direct response business in-line with the market.' While we acknowledge the potential of SNAP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Chef's Line, Glenview Farms Parent US Foods Maintains Revenue Outlook Despite Q2 Miss
US Foods Holding Corp. (NYSE:USFD) shares are trading lower on Thursday after the company reported second-quarter results. US Foods Holding Corp. markets and sells products under various brands, including Chef's Line, Stock Yards, Metro Deli, Harvest Value, Monarch, Monogram, Molly's Kitchen, and Glenview Farms. They also distribute foodservice equipment and supplies under brands like Chef'Stores, Food Fanatics, and Smart Foodservice. It clocked second-quarter adjusted earnings per share of $1.19, beating the analyst consensus estimate of $1.13. Quarterly sales of $10.082 billion (up 3.8% year over year) missed the Street view of $10.166 billion. "We delivered top-line growth and margin expansion combined with accretive share buybacks, which resulted in 28% Adjusted EPS growth," said CFO Dirk sales growth was driven by case volume growth and food cost inflation of 2.5%. Total case volume increased 0.9% from the prior year, driven by a 2.7% increase in independent restaurant case volume, a 4.9% increase in healthcare volume and a 2.4% increase in hospitality volume, US Foods Holding said in a press release. Adjusted gross profit increased by $85 million year-over-year (up 5.0%) to $1.8 billion. It represented 17.8% of net sales, compared with 17.6% in the year-ago period. View more earnings on USFD Adjusted EBITDA of $548 million, increased by 12.1%, from the prior year. Adjusted EBITDA margin was 5.4%, an increase of 40 basis points compared to the prior year. The company said it has secured over $50 million in year-to-date cost-of-goods savings through strategic vendor management and is positioned to exceed its $260 million 2027 commitment. Private-label penetration climbed more than 80 basis points to over 53% in core independent restaurants, driving improved margins. Enhanced inventory controls are projected to deliver a $30 million gross profit benefit in 2025, while $45 million in indirect-spend savings this year will further reduce operating expenses. The company exited the quarter with cash and equivalents worth $61 million, higher than $59 million in the year-ago period. Outlook US Foods Holding affirmed its fiscal year 2025 sales guidance at $39.392 billion to $40.150 billion, compared with the consensus estimate of $39.764 billion. The company also narrowed its adjusted EPS guidance for fiscal 2025 to $3.76–$3.87, tightening the prior range of $3.69–$3.88, and compared with the street estimate of $3.81. Price Action: USFD shares are trading lower by 8.56% to $77.39 at last check Thursday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Chef's Line, Glenview Farms Parent US Foods Maintains Revenue Outlook Despite Q2 Miss originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Geo Group (GEO) Falls 11.46% on Lower Earnings Outlook
We recently published . The GEO Group Inc. (NYSE:GEO) is one of the worst-performing stocks on Wednesday. The GEO Group slashed its share prices by 11.46 percent on Wednesday to close at $22.88 apiece as investors soured on the lower-than-expected earnings outlook for full-year 2025, shunning its impressive income performance in the second quarter of the year. In an updated report, The GEO Group Inc. (NYSE:GEO) raised its 2025 revenue target to $2.56 billion, up from the $2.53 billion guidance previously. However, analysts had expected $2.58 billion. Additionally, The GEO Group Inc. (NYSE:GEO) expects attributable net income to be in a range of $1.99 to $2.09 per diluted share, including a $228 million gain on the sale of its Lawton Facility. Adjusted EBITDA was pegged at $465 million to $490 million. In the second quarter of the year, The GEO Group Inc. (NYSE:GEO) swung to an attributable net income of $29 million from a $32.5 million net loss in the same period last year. Revenues grew by 4.8 percent to $636 million from $608 million year-on-year. Photo by Anthony Tran on Unsplash In the first half, attributable net income ended at $48.7 million, reversing a net loss of $9.8 million in the same comparable period. Revenues inched up by 2.5 percent to $1.24 billion from $1.21 billion year-on-year. While we acknowledge the potential of GEO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
